Trial Profile
An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk for Developing Complications
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jul 2023
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary) ; Adalimumab; Methotrexate
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Takeda
- 11 Jul 2022 Status changed from active, no longer recruiting to completed.
- 22 Sep 2021 An additional dose of Adalimumab (80 mg) has been added to the treatments section along with the previously existing doses of 160 and 40 mg.
- 15 Jul 2020 Planned End Date changed from 13 Sep 2022 to 14 Jul 2022.